Skip to main content

Table 4 Current PHASE III trials

From: Maintenance therapy in NSCLC: why? To whom? Which agent?

Trial/Author

Comparison

Comments

References

NCT01107626 ECOG 5508

Paclitaxel/Carboplatin/Bevacizumab, followed by pemetrexed vs bevacizumab vs pemetrexed/bevacizumab

not yet open for recruitment

[39]

NCT00789373 Paz-Ares LG

Maintenance Pemetrexed/BSC Vs BSC Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Nonsquamous NSCLC

currently recruiting

[39]

NCT00762034 Patel et al.

Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab vs Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in IIIB or IV Nonsquamous NSCLC

currently recruiting

[39]

NCT00820755 NEXT

Platinum-based chemotherapy plus cetuximab followed by cetuximab as maintenance with either 500 mg/m2 every 2 w or 250 mg/m2 every w

ongoing, not recruiting

[39]

NCT00948675 Zinner et al.

Pemetrexed/carboplatin with maintenance pemetrexed vs paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab in IIIB or IV Nonsquamous NSCLC

currently recruiting

[39]

NCT00693992 CALGB 30607

Sunitinib as maintenance therapy vs placebo in Non-Progressing Patients Following 4 Cycles of Platinum-Based Combination in IIIB/IV NSCLC

currently recruiting

[39]

NCT00961415 AVAPERL1

Bevacizumab with or without pemetrexed as maintenance after 4 cycles Bevacizumab/Cisplatin/Pemetrexed

currently recruiting

[39]

NCT00676507 STOP

Lucanix™ (Belagenpumatucel-L) as Maintenance III/IV NSCLC with SD or PR and Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy

currently recruiting

[39]